OREXO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.4 SEK | -4.67% |
|
-3.55% | +31.95% |
| 05-08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
| 04-17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OREXO AB | Specialty & Advanced Pharmaceuticals | -4.67% | -3.55% | +31.95% | +96.15% | -73.05% | 66.01M |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- ORX Stock
- Charts Orexo AB
- Comparison Chart
